



UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 19 2010

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Donald R. Steinberg
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, MA 02109

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,196,404

Dear Mr. Steinberg :

Pursuant to order by the United States District Court for the Eastern District of Virginia, Alexandria Division in *The Medicines Company v. David Kappos et al.* in civil action no. 01:10-cv-81, the USPTO issued an interim extension under the provision of 35 U.S.C. § 156(e)(2) on March 18, 2010. The attached document corrects an error in the Interim Extension granted on March 18, 2010. The order granting the interim extension was revised to read as follows:

An interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 5,196,404 is granted for a period of 61 days from the original expiration date of the patent, to and including May 23, 2010.

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: Angiomax
FDA Docket No.: 01E-0213

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Biogen Idec MA Inc. : CORRECTION TO THE
Request for Patent Term Extension : ORDER GRANTING
U.S. Patent No. 5,196,404 : INTERIM EXTENSION

Biogen Idec MA Inc., the owner of record in the United States Patent and Trademark Office (USPTO) of U.S. Patent No. 5,196,404 (the '404 patent), through its authorized agent, The Medicines Company, filed an application for patent term extension under 35 U.S.C. § 156 on February 14, 2001. ~~The original term of the patent is due to expire on March 23, 2010.~~ The patent claims the active ingredient bivalirudin, in the human drug product Angiomax®, which was approved by the Food and Drug Administration for commercial marketing or use on December 15, 2000. An extension of 1,728 days is requested.

Pursuant to order by the United States District Court for the Eastern District of Virginia, Alexandria Division in *The Medicines Company v. David Kappos et al.* in civil action no. 01:10-cv-81, the USPTO issued an interim extension under the provision of 35 U.S.C. § 156(e)(2) on March 18, 2010. The order granting the interim extension is revised to read as follows:

An interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 5,196,404 is granted for a period of 61 days from the original expiration date of the patent, to and including May 23, 2010.

3/19/2010
Date



David J. Kappos
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office